Intracameral treatment significantly reduces postoperative CME compared with topical steroids

Posted on

Intracameral phenylephrine/ketorolac and topical NSAIDS significantly reduced postoperative cystoid macular edema (CME), breakthrough iritis, and pain after cataract surgery compared with topical steroids and NSAIDS, according to a presentation at the 2020 ASCRS Virtual Meeting.

In this retrospective 2-cohort study, 2218 eyes of 1402 patients undergoing cataract surgery received either intracameral phenylephrine 1.0%/ketorolac 0.3% during or topical loteprednol 0.5% 2 days postoperatively, tapered over the course of 4 weeks.

Researchers found that the incidence of CME was approximately 3 times lower in the study group. Significantly lower incidence rates of iritis and pain were found in the study group.

“These findings suggest that phenylephrine/ketorolac may be a better prophylactic regimen for postoperative CME, breakthrough iritis, and pain than regimens involving compliance-dependent topical steroids and topical NSAIDs,” concluded the presenter.

Visco DM, et al. Effect of intracameral phenylephrine 1.0%/ketorolac 0.3% on cystoid macular edema, breakthrough iritis, and pain following cataract surgery. Presented at: 2020 ASCRS Virtual Meeting

Related Articles
How do patients use social media after cataract surgery?
Jul 29, 2021
Cataract surgery reduces average number ocular hypotensive medications
Jul 22, 2021
American Academy of Ophthalmology and ASCRS Urge Aetna to Reverse Disruptive New Policy on Cataract Surgery
Jul 05, 2021